



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Daniel H. Teitelbaum
Serial No.: 10/798,470
Filed: 03/11/2004
Entitled: **Angiotensin Converting Enzyme Inhibitor Use For Treatment And Prevention Of Gastrointestinal Disorders**

Art Unit.: 1614
Examiner: P.G. Spivack


**INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 3, 2006.

By:


Mary Ellen Waite


Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

A check for \$180.00 is also enclosed pursuant to 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement after three months as set forth in C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: May 3, 2006


David A. Casimir
Registration No. 42,395

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
608/218-6900




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Daniel H. Teitelbaum
Serial No.: 10/798,470 Art Unit.: 1614
Filed: 03/11/2004 Examiner: P.G. Spivack
Entitled: **Angiotensin Converting Enzyme Inhibitor Use For Treatment And
Prevention Of Gastrointestinal Disorders**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Sir or Madam:


The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- U.S. Patent No. 4,473,575
- U.S. Patent No. 4,385,051
- U.S. Patent No. 4,344,949
- U.S. Patent No. 6,267,990
- EP 80822
- EP 60668
- UK 2103614
- EP 79-022

- Kirsner, J. B., et al. (eds), Inflammatory Bowel Disease, 3rd ed., Lea and Febiger, Philadelphia (1988). This is a book and is not being supplied at this time.
- Zipser, R. D., (ed.), Dig. Dis. Sci., 33 Suppl.:1S-87S (1988)
- Schappi et al., Arch. Dis. Child., 1984:147 (2001)
- Noguchi et al., Jap. J. Pharmacol. 40(3):373-80 (1986)
- Nussberger et al., J. Cardiovasc. Pharmacol. 9(1):39-44 (1987)
- Attwood, et al., FEBS Lett. 165(2):201-6 (1984)
- Takata et al., Clin. Exp. Pharmacol. Physiol. 10:131 (1983)
- Acta. Pharmacol. Toxicol. 59 (Supp. 5):1:224 (1986) (No Authors Listed)
- (This reference is not being supplied at this time)
- Acta. Pharmacol. Toxicol. 59 (Supp. 5):2:342 (1986) (No Authors Listed)
- (This reference is not being supplied at this time)
- Sybertz et al., J. Cardiovasc. Pharmacol. 5(4):643, 655 (1983)
- Lees, Eur. J. Clin. Pharmacol. 31(5):519-24 (1987)
- Kim et al., J. Med. Chem. 26:394 (1983)
- Baum et al., J. Cardiovasc. Pharmacol. 5(4):655 (1983)

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: 5/3/06


David A. Casimir
Registration No. 42,395
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/798,470
		Filing Date	03/11/2004
		First Named Inventor	Teitelbaum
		Art Unit	1614
		Examiner Name	P.G. Spivack
Sheet 2	of 3	Attorney Docket Number	UM-08764

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published:	T ²
	9	Kirsner, J. B., et al. (eds), Inflammatory Bowel Disease, 3rd ed., Lea and Febiger, Philadelphia (1988). This is a book and is not being supplied at this time.	
	10	Zipser, R. D., (ed.), Dig. Dis. Sci., 33 Suppl.:1S-87S (1988)	
	11	Schappi et al., Arch. Dis. Child., 1984:147 (2001)	
	12	Noguchi et al., Jap. J. Pharmacol. 40(3):373-80 (1986)	
	13	Nussberger et al., J. Cardiovasc. Pharmacol. 9(1):39-44 (1987)	
	14	Attwood, et al., FEBS Lett. 165(2):201-6 (1984)	
	15	Takata et al., Clin. Exp. Pharmacol. Physiol. 10:131 (1983)	
	16	Acta. Pharmacol. Toxicol. 59 (Supp. 5):1:224 (1986) (No Authors Listed) (This reference is not being supplied at this time)	
	17	Acta. Pharmacol. Toxicol. 59 (Supp. 5):2:342 (1986) (No Authors Listed) (This reference is not being supplied at this time)	
	18	Sybertz et al., J. Cardiovasc. Pharmacol. 5(4):643, 655 (1983)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/798,470
		Filing Date	03/11/2004
		First Named Inventor	Teitelbaum
		Art Unit	1614
		Examiner Name	P.G. Spivack
Sheet 3	of 3	Attorney Docket Number UM-08764	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	19	Lees, Eur. J. Clin. Pharmacol. 31(5):519-24 (1987)	
	20	Kim et al., J. Med. Chem. 26:394 (1983)	
	21	Baum et al., J. Cardiovasc. Pharmacol. 5(4):655 (1983)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.